Has Jeffrey Tamsing, MD received payments from drug or device companies?

Yes. Drug and device makers reported $179,625 in general payments to Jeffrey Tamsing, MD across 1,776 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jeffrey Tamsing, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jeffrey Tamsing, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jeffrey Tamsing, MD

Neurology · Parker, CONPI 1457518680

Payments from drug & device makers

$179,625in general payments, 2019–2025

Across 1,776 payments — averaging $101.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$89K
Lilly USA, LLC$39K
Argenx US, Inc.$25K
AbbVie$4K
Amgen$3K
UCB, Inc.$1K
plus $17K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	202	$89,470
Lilly USA, LLC	145	$39,044
Argenx US, Inc.	54	$25,007
AbbVie(2 entities)	248	$3,965
Amgen(2 entities)	50	$3,030
UCB, Inc.	47	$1,245
Pfizer	85	$1,208
Bristol Myers Squibb	46	$1,167
Neurocrine Biosciences, Inc.	83	$1,112
Novartis	80	$1,096
Teva Pharmaceuticals USA, Inc.	72	$1,090
Lundbeck LLC	56	$1,082
Biogen	61	$1,059
Tanabe Pharma America, Inc.	51	$821
Sanofi	36	$665
SK Life Science, Inc.	25	$588
Neurelis, Inc.	19	$468
MDD US Operations, LLC	22	$406
Supernus Pharmaceuticals, Inc.	26	$386
Vanda Pharmaceuticals Inc.	11	$372
CSL Behring	18	$346
Akcea Therapeutics, Inc.	21	$334
Eisai Inc.	16	$322
Johnson & Johnson(2 entities)	11	$321
Biohaven Pharmaceutical Holding Company Ltd.	18	$248
Acadia Pharmaceuticals Inc	14	$242
GRT US Holding, Inc.	14	$219
Grifols USA, LLC	10	$181
Avanir Pharmaceuticals, Inc.	11	$170
Alnylam Pharmaceuticals Inc.	7	$169
Livanova USA, Inc.	10	$169
Mallinckrodt Hospital Products Inc.	10	$161
Adamas Pharmaceuticals, Inc.	8	$158
Catalyst Pharmaceuticals, Inc.	7	$156
Biohaven Pharmaceuticals, Inc.	9	$148
Takeda Pharmaceuticals U.S.A., Inc.	8	$148
Zyla Life Sciences, Inc.	20	$140
Sobi, Inc	6	$116
EDW Pharma, Inc.	1	$111
EMD Serono, Inc.	6	$104
Sunovion Pharmaceuticals Inc.	9	$104
Abbott	5	$101
Impel Pharmaceuticals Inc.	5	$100
Otsuka America Pharmaceutical, Inc.	5	$100
Merz Pharmaceuticals, LLC	5	$98
Kyowa Kirin, Inc.	5	$97
Banner Life Sciences, LLC	5	$92
Amneal Pharmaceuticals LLC	5	$81
E.r. Squibb & Sons, L.L.C.	5	$77
Merz North America, Inc.	4	$72
Mallinckrodt Enterprises LLC	4	$68
Scilex Pharmaceuticals Inc.	4	$67
Octapharma USA, Inc.	3	$67
Arbor Pharmaceuticals, Inc.	5	$66
Collegium Pharmaceutical, Inc.	4	$66
Bausch Health US, LLC	3	$65
Aquestive Therapeutics, Inc.	3	$56
Upsher-smith Laboratories LLC	4	$55
Boston Scientific	3	$55
Amylyx Pharmaceuticals, Inc.	2	$48

How this compares

$179,625 in reported general payments places this provider in the 85th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado →

Medicare billing

Part B allowed, 2024

$389,628

Medicare patients

474

Services billed

37,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Parker

Ravi ShahParker$1.3M
Enrique AlvarezAurora$14.3M
Rajeev KumarEnglewood$14.3M
Tamara MillerFort Collins$7.4M
Alison AllenBasalt$4.6M
Adam WolffDenver$2.4M
Kimberly WagnerColorado Springs$2.3M
Timothy VollmerAurora$2M
Jeffrey BennettAurora$1.9M
William WagnerLouisville$1.5M

See the full list for Colorado →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →